Pathogenic Mechanisms of Bacillus Endophthalmitis
芽孢杆菌眼内炎的致病机制
基本信息
- 批准号:10428514
- 负责人:
- 金额:$ 34.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAnteriorAnti-Inflammatory AgentsAntibioticsAreaAttenuatedBacillusBacillus cereusBacteriaBacterial InfectionsBehaviorBiologyBlindnessCell WallCellsChemotaxisCholesterolClinicalCommunicable DiseasesDataDeacetylationDiseaseEffectivenessElementsEndophthalmitisEnvironmentEnzymesEventEvolutionEyeEye InjuriesFailureFamilyFlagellaFunctional disorderGerminationGoalsGrowthImmuneIn VitroInfectionInflammationInflammatoryInflammatory ResponseLipoproteinsMediatingMotionNeutrophilic InfiltrateNutrientOperative Surgical ProceduresOrganismOutcomeOxygenPathogenesisPathogenicityPathway interactionsPatient-Focused OutcomesPatientsPeptidoglycanPharmaceutical PreparationsPhasePreventionReportingReproduction sporesResearchRetinaRoleSavingsSepsisSignal TransductionStrategic PlanningStructureSuperoxide DismutaseSurfaceSystemTLR2 geneTLR4 geneTeichoic AcidsTemperatureTestingTherapeuticTherapeutic InterventionTherapeutic UsesTimeTissuesToxinTraumaVegetative StatesVirulenceVisionVisualbacterial endophthalmitiscell motilitycell typeeffective therapyimprovedin vivoineffective therapiesinhibitorinnate immune pathwaysmembermigrationmutantneutrophilnovelpathogenpreservationpreventquorum sensingretinal damagetargeted treatmenttherapeutically effectivetranscriptome sequencingtranscriptomicstreatment strategy
项目摘要
PROJECT SUMMARY / ABSTRACT
Intraocular bacterial infections (endophthalmitis) cause a significant number of cases of blindness
worldwide. Efforts to prevent damage to delicate ocular tissues during infection rely on swift and proper use of
therapeutics to rapidly kill organisms and arrest potentially damaging inflammation. Currently-used antibiotics
can kill organisms, but the effectiveness of anti-inflammatory drugs is controversial. No current therapies
neutralize toxins which damage nonregenerative tissues in the eye. Our overarching goal is to develop
more effective therapeutics which target and inhibit these events, preserving vision.
Bacillus cereus (Bc) causes one of the most inflammatory and rapidly blinding forms of
endophthalmitis. This common environmental organism enters the eye during trauma or bloodstream
infection, and is also a reported surgical contaminant. Eyes infected with Bc can be rendered sightless in a
short period of time, so effective treatment is critical to saving vision. This proposal focuses on mechanisms
related to the organism and its behavior in the eye, and highlights events during the infection course prior to
significant retinal damage and inflammation—a time when therapeutic intervention would be most valuable. We
propose four aims that address Bc pathogenesis during important early events in endophthalmitis:
Aim 1 will analyze elements of the intraocular environment that trigger germination of Bc spores. The
mechanisms involved in transformation from spore to vegetative state in the eye will be examined.
Aim 2 will further explore innate immune pathway recognition of potential Bc agonists. For TLR2, we will
address the role of peptidoglycan deacetylation and teichoic acid as agonists. For TLR4, we will address
the role of cereolysin and heat-labile surface components as agonists.
Aim 3 will examine whether intraocular inflammation prompts migration of Bc throughout the eye.
RNASeq data suggest that flagellar and motility systems of Bc are highly expressed in vivo.
Aim 4 will test the hypothesis that during inflammation, products secreted by Bc disarm infiltrating
neutrophils. Candidates include superoxide dismutase, immune inhibitor A, and cereolysin, and mutants
deficient in each will be tested for potential anti-neutrophil activity.
These independent but related aims are a logical extension of our ongoing research into the pathogenic
mechanisms underlying bacterial endophthalmitis. For Bc endophthalmitis patients, ineffective treatment
often results in significant vision loss or loss of the globe itself. Therefore, identifying factors and
pathways important to early disease events disease is critical to developing novel and effective therapeutic
options for this blinding infection.
项目摘要/摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michelle C Callegan其他文献
Michelle C Callegan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michelle C Callegan', 18)}}的其他基金
Pathogenic Mechanisms of Bacillus Endophthalmitis
芽孢杆菌眼内炎的致病机制
- 批准号:
10178032 - 财政年份:2018
- 资助金额:
$ 34.74万 - 项目类别:
Pathogenic Mechanisms of Bacillus Endophthalmitis
芽孢杆菌眼内炎的致病机制
- 批准号:
9759927 - 财政年份:2018
- 资助金额:
$ 34.74万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 34.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 34.74万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 34.74万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 34.74万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 34.74万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 34.74万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 34.74万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 34.74万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 34.74万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 34.74万 - 项目类别:














{{item.name}}会员




